AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

BARDA - ASPR / DAAPPO / BARDA DCMA

Contract Value

Not provided

Codes & Classification
Solicitation Number

RRPV-AVAT_PATH-SM

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

-

SourceSAM
Documents1
The Department of Health and Human Services, through the Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA), has issued a Sources Sought notice titled "AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses." This Request for Information (RFI), posted under procurement identifier RRPV-AVAT_PATH-SM, seeks to conduct comprehensive market research to identify organizations with advanced capabilities in artificial intelligence (AI) and related computational methods for the discovery and development of broad-spectrum small-molecule therapeutics targeting filoviruses, including Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV). **Purpose and Scope** The primary objective of this RFI is to gather information on technical capabilities, infrastructure, prior experience, and recommended approaches relevant to AI-driven drug discovery for filoviruses. BARDA is particularly interested in organizations that can leverage AI-enabled design, conduct in vitro verification of candidate molecules, and perform early preclinical proof-of-concept evaluations. The information collected will inform future acquisition planning and may shape the scope and structure of a subsequent solicitation. Respondents are encouraged to propose teaming arrangements or partnerships to address the full range of capabilities described. **Key Requirements and Objectives** Respondents are asked to provide detailed information on their strategic and technical approaches to discovering and advancing potent, safe, broad-spectrum small-molecule inhibitors of filoviruses. Areas of interest include: - AI and in silico drug discovery platforms, including data assets, molecular design and optimization, modeling and simulation capabilities, and strategies for synthetic feasibility and developability. - Experience with small-molecule modalities, including novel chemical structures, peptides, and other synthetic molecules, with a focus on direct-acting antivirals or host-targeted approaches relevant to viral replication. - Integration of AI-driven design with medicinal chemistry, ADME/Tox prediction, and experimental verification, including methods for assessing antiviral activity, safety, selectivity, and off-target risks. - Approaches to model improvement and optimization, including the incorporation of experimental data into iterative design cycles. - Experience with small animal models and early preclinical development for viral pathogens. - Strategies for achieving broad-spectrum activity across multiple filovirus species and, where applicable, related RNA virus families. - Intellectual property considerations and freedom-to-operate for AI-assisted drug design. - Willingness to participate in partner-matching mechanisms and identification of potential capability gaps. Respondents are also asked to provide high-level estimates for timelines and rough-order-of-magnitude costs for progressing from in silico design to in vivo proof-of-concept, as well as to describe key challenges associated with such efforts. **Contracting Entity and Classification Details** This notice is issued by BARDA under the ASPR/DAAPPO/BARDA DCMA office, a federal entity within the Department of Health and Human Services. The procurement is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with Product Service Code AN13. There are no set-aside requirements for this opportunity. **Submission Instructions and Special Considerations** Interested parties should submit a written response, including a cover page with administrative and contact information and a technical response (no longer than five pages, in PDF or Word format, minimum 10-point font). The cover page should include the entity name, headquarters, mailing address, and contact details. Responses should be concise, technically focused, and address the specific questions outlined in the RFI. Detailed cost proposals, full development plans, or proprietary data are not requested at this stage. All submissions must be clearly marked with appropriate restrictive legends to protect confidential or proprietary information. Classified information should not be submitted. Responses must be submitted via email to [email protected] no later than 1:00 PM EDT on June 17, 2026. Late submissions will not be considered. While submission is voluntary and does not commit respondents to future participation, only members of the RRPV consortium will be eligible to respond to any subsequent Request for Project Proposals (RPP) that may be issued. BARDA reserves the right to further engage with respondents for clarification but will not provide feedback on submissions. **Constant Elements and Long-Term Considerations** This RFI is for information gathering only and does not constitute a solicitation or imply any obligation to issue a future solicitation or make an award. The focus on AI-enabled discovery, broad-spectrum small-molecule therapeutics, and the targeting of high-consequence filoviruses will remain central throughout the contract lifecycle. The requirement for BSL-4 containment, the emphasis on direct-acting antivirals, and the exclusion of nucleic acid-based therapeutics and prophylactic candidates are also expected to remain constant. **Contact and Additional Information** - Contracting Entity: BARDA - ASPR / DAAPPO / BARDA DCMA - Department: Health and Human Services, Department of - Agency: Office of Assistant Secretary for Preparedness and Response - NAICS Code: 541714 (Research and Development in Biotechnology, except Nanobiotechnology) - Product Service Code: AN13 - Primary Contact: [email protected] - Notice URL: [https://sam.gov/opp/2cc0372f83ed49b694738d85f0ff495e/view](https://sam.gov/opp/2cc0372f83ed49b694738d85f0ff495e/view) - Notice Status: Active Contractors with expertise in AI-driven drug discovery, antiviral development, and preclinical evaluation for high-consequence viral pathogens are encouraged to review the full RFI and consider submitting a response to inform BARDA’s future program development in this critical area.